Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.50 |
| ▸ | LPL | P06858 | 8/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22173457 | 0.94 | LIPG (0.52) | LIPGLPLESR1ESR2PDK2 | |
| SCHEMBL22173461 | 0.92 | LIPG (0.61) | LIPGLPLESR1ESR2PDK2 | |
| SCHEMBL29603064 | 0.92 | LIPG (0.44) | LIPGLPLESR1ESR2KDM4E | |
| SCHEMBL17470489 | 0.92 | LIPG (0.44) | LIPGLPLESR1ESR2KDM4E | |
| SCHEMBL12166505 | 0.92 | LIPG (0.43) | LIPGLPLESR1ESR2KDM4E | |
| SCHEMBL22173210 | 0.91 | LIPG (0.60) | LIPGLPLESR1ESR2PDK2 | |
| SCHEMBL17816784 | 0.91 | LIPG (0.43) | LIPGLPLESR1ESR2KDM4E | |
| SCHEMBL22173327 | 0.90 | LIPG (0.58) | LIPGLPLESR1ESR2PDK2 | |
| SCHEMBL21922806 | 0.89 | LIPG (0.42) | LIPGLPLESR1ESR2PDK2 | |
| SCHEMBL17143248 | 0.88 | LIPG (0.48) | LIPGLPLESR1ESR2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-05-04 | — | — | US | disclosed |
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO LTD (KR) | 2023-05-04 | — | — | US | disclosed |
| US-11542252-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-01-03 | — | — | US | disclosed |
| US-20200207739-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542252-B2 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | LIPG 4659/4885LPL 3627/4885ESR1 147/4885 |
| US-20230140682-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | LIPG 4659/4885LPL 3627/4885ESR1 147/4885 |
| US-20200207739-A1 | Heterocyclic compound, composition including the same, and organic light-emitting device including the heterocyclic compound | CCNT1, CCNA1, CYP1B1 | LIPG 4659/4885LPL 3627/4885ESR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.